JPWO2020247372A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247372A5 JPWO2020247372A5 JP2021571944A JP2021571944A JPWO2020247372A5 JP WO2020247372 A5 JPWO2020247372 A5 JP WO2020247372A5 JP 2021571944 A JP2021571944 A JP 2021571944A JP 2021571944 A JP2021571944 A JP 2021571944A JP WO2020247372 A5 JPWO2020247372 A5 JP WO2020247372A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- bone marrow
- syndrome
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002798 bone marrow cell Anatomy 0.000 claims description 168
- 210000004027 cell Anatomy 0.000 claims description 161
- 239000003795 chemical substances by application Substances 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 128
- 210000002540 macrophage Anatomy 0.000 claims description 115
- 230000000694 effects Effects 0.000 claims description 113
- 206010028980 Neoplasm Diseases 0.000 claims description 110
- 239000000427 antigen Substances 0.000 claims description 89
- 108091007433 antigens Proteins 0.000 claims description 89
- 102000036639 antigens Human genes 0.000 claims description 89
- 230000027455 binding Effects 0.000 claims description 88
- 201000011510 cancer Diseases 0.000 claims description 81
- 239000012634 fragment Substances 0.000 claims description 79
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 72
- 210000000066 myeloid cell Anatomy 0.000 claims description 72
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 61
- 230000002757 inflammatory effect Effects 0.000 claims description 56
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 44
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 41
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 37
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 36
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 36
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 36
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 36
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 33
- 210000004322 M2 macrophage Anatomy 0.000 claims description 32
- 210000004443 dendritic cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- 210000000440 neutrophil Anatomy 0.000 claims description 31
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 25
- 230000028327 secretion Effects 0.000 claims description 23
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 210000001616 monocyte Anatomy 0.000 claims description 22
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 20
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 20
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 15
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 15
- 230000006044 T cell activation Effects 0.000 claims description 15
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 210000000822 natural killer cell Anatomy 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 239000002955 immunomodulating agent Substances 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 230000007115 recruitment Effects 0.000 claims description 12
- 230000009885 systemic effect Effects 0.000 claims description 12
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 11
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 11
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 11
- 108010009992 CD163 antigen Proteins 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 11
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 11
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 11
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 11
- 101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 claims description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 11
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 11
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 11
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 11
- 108010065805 Interleukin-12 Proteins 0.000 claims description 11
- 102000003810 Interleukin-18 Human genes 0.000 claims description 11
- 108090000171 Interleukin-18 Proteins 0.000 claims description 11
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 11
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims description 11
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 11
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 11
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims description 11
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 11
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 11
- 210000001787 dendrite Anatomy 0.000 claims description 11
- 102000045929 human SIGLEC9 Human genes 0.000 claims description 11
- 238000000386 microscopy Methods 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 230000002601 intratumoral effect Effects 0.000 claims description 10
- 230000002147 killing effect Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 238000010171 animal model Methods 0.000 claims description 9
- 229940022399 cancer vaccine Drugs 0.000 claims description 9
- 238000009566 cancer vaccine Methods 0.000 claims description 9
- 208000005017 glioblastoma Diseases 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- -1 TGFb Proteins 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
- 241000282567 Macaca fascicularis Species 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 7
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 6
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 6
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims description 6
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 6
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 238000002626 targeted therapy Methods 0.000 claims description 5
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 4
- 208000024312 invasive carcinoma Diseases 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 230000001235 sensitizing effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 3
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 238000011374 additional therapy Methods 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims description 3
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims description 3
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 3
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000030173 low grade glioma Diseases 0.000 claims description 3
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 208000007312 paraganglioma Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000002918 testicular germ cell tumor Diseases 0.000 claims description 3
- 208000008732 thymoma Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 claims description 2
- 101000863880 Homo sapiens Sialic acid-binding Ig-like lectin 6 Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 claims description 2
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 claims description 2
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 2
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 claims description 2
- 101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 claims description 2
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 claims description 2
- 102100027093 Sialic acid-binding Ig-like lectin 12 Human genes 0.000 claims description 2
- 101710143288 Sialic acid-binding Ig-like lectin 12 Proteins 0.000 claims description 2
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 claims description 2
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 claims description 2
- 102100029947 Sialic acid-binding Ig-like lectin 6 Human genes 0.000 claims description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 2
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 claims description 2
- 102100032855 Sialoadhesin Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 238000012575 bio-layer interferometry Methods 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 230000034994 death Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims 21
- 208000026278 immune system disease Diseases 0.000 claims 16
- 230000001363 autoimmune Effects 0.000 claims 15
- 201000004624 Dermatitis Diseases 0.000 claims 12
- 206010014801 endophthalmitis Diseases 0.000 claims 12
- 206010025135 lupus erythematosus Diseases 0.000 claims 12
- 206010020751 Hypersensitivity Diseases 0.000 claims 9
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 9
- 206010001889 Alveolitis Diseases 0.000 claims 6
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 6
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 6
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 6
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 6
- 201000002481 Myositis Diseases 0.000 claims 6
- 241000721454 Pemphigus Species 0.000 claims 6
- 208000031845 Pernicious anaemia Diseases 0.000 claims 6
- 206010035664 Pneumonia Diseases 0.000 claims 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 6
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 230000007815 allergy Effects 0.000 claims 6
- 208000010668 atopic eczema Diseases 0.000 claims 6
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 201000001981 dermatomyositis Diseases 0.000 claims 6
- 230000002124 endocrine Effects 0.000 claims 6
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 6
- 208000024908 graft versus host disease Diseases 0.000 claims 6
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 6
- 208000000509 infertility Diseases 0.000 claims 6
- 230000036512 infertility Effects 0.000 claims 6
- 231100000535 infertility Toxicity 0.000 claims 6
- 208000008795 neuromyelitis optica Diseases 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 206010039083 rhinitis Diseases 0.000 claims 6
- 206010043207 temporal arteritis Diseases 0.000 claims 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000026872 Addison Disease Diseases 0.000 claims 3
- 206010001324 Adrenal atrophy Diseases 0.000 claims 3
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 3
- 208000024985 Alport syndrome Diseases 0.000 claims 3
- 208000035939 Alveolitis allergic Diseases 0.000 claims 3
- 206010001935 American trypanosomiasis Diseases 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 3
- 208000027496 Behcet disease Diseases 0.000 claims 3
- 208000005024 Castleman disease Diseases 0.000 claims 3
- 208000024699 Chagas disease Diseases 0.000 claims 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 3
- 208000010007 Cogan syndrome Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000014311 Cushing syndrome Diseases 0.000 claims 3
- 206010011715 Cyclitis Diseases 0.000 claims 3
- 206010063057 Cystitis noninfective Diseases 0.000 claims 3
- 208000016192 Demyelinating disease Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 3
- 208000021866 Dressler syndrome Diseases 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 3
- 206010015218 Erythema multiforme Diseases 0.000 claims 3
- 206010015226 Erythema nodosum Diseases 0.000 claims 3
- 208000030644 Esophageal Motility disease Diseases 0.000 claims 3
- 208000004332 Evans syndrome Diseases 0.000 claims 3
- 208000027445 Farmer Lung Diseases 0.000 claims 3
- 208000028387 Felty syndrome Diseases 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 3
- 208000036495 Gastritis atrophic Diseases 0.000 claims 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 3
- 208000003807 Graves Disease Diseases 0.000 claims 3
- 208000015023 Graves' disease Diseases 0.000 claims 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 3
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 3
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 3
- 208000031814 IgA Vasculitis Diseases 0.000 claims 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 3
- 206010021263 IgA nephropathy Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010067737 Lupus hepatitis Diseases 0.000 claims 3
- 208000027530 Meniere disease Diseases 0.000 claims 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 3
- 208000000112 Myalgia Diseases 0.000 claims 3
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 3
- 208000021908 Myocardial disease Diseases 0.000 claims 3
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 3
- 208000014934 Oesophageal motility disease Diseases 0.000 claims 3
- 206010031252 Osteomyelitis Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 206010065159 Polychondritis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000006311 Pyoderma Diseases 0.000 claims 3
- 208000003782 Raynaud disease Diseases 0.000 claims 3
- 208000033464 Reiter syndrome Diseases 0.000 claims 3
- 206010038910 Retinitis Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 3
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 3
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 3
- 206010043189 Telangiectasia Diseases 0.000 claims 3
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 3
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 3
- 208000003441 Transfusion reaction Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 3
- 206010047642 Vitiligo Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 208000030961 allergic reaction Diseases 0.000 claims 3
- 208000004631 alopecia areata Diseases 0.000 claims 3
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 230000036783 anaphylactic response Effects 0.000 claims 3
- 208000003455 anaphylaxis Diseases 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 3
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 3
- 201000011191 dyskinesia of esophagus Diseases 0.000 claims 3
- 201000002491 encephalomyelitis Diseases 0.000 claims 3
- 206010014665 endocarditis Diseases 0.000 claims 3
- 231100000321 erythema Toxicity 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 208000022195 farmer lung disease Diseases 0.000 claims 3
- 208000001031 fetal erythroblastosis Diseases 0.000 claims 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 3
- 208000018090 giant cell myocarditis Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 208000003215 hereditary nephritis Diseases 0.000 claims 3
- 230000001900 immune effect Effects 0.000 claims 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000000366 juvenile effect Effects 0.000 claims 3
- 201000011486 lichen planus Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 3
- 208000005987 polymyositis Diseases 0.000 claims 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000002574 reactive arthritis Diseases 0.000 claims 3
- 230000000306 recurrent effect Effects 0.000 claims 3
- 230000001850 reproductive effect Effects 0.000 claims 3
- 201000003068 rheumatic fever Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 3
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000009056 telangiectasis Diseases 0.000 claims 3
- 206010043778 thyroiditis Diseases 0.000 claims 3
- 208000005057 thyrotoxicosis Diseases 0.000 claims 3
- 208000009174 transverse myelitis Diseases 0.000 claims 3
- 230000005951 type IV hypersensitivity Effects 0.000 claims 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 3
- 206010047470 viral myocarditis Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857194P | 2019-06-04 | 2019-06-04 | |
| US62/857,194 | 2019-06-04 | ||
| US201962867577P | 2019-06-27 | 2019-06-27 | |
| US62/867,577 | 2019-06-27 | ||
| US202063032292P | 2020-05-29 | 2020-05-29 | |
| US63/032,292 | 2020-05-29 | ||
| PCT/US2020/035703 WO2020247372A1 (en) | 2019-06-04 | 2020-06-02 | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535417A JP2022535417A (ja) | 2022-08-08 |
| JP2022535417A5 JP2022535417A5 (https=) | 2023-06-12 |
| JPWO2020247372A5 true JPWO2020247372A5 (https=) | 2023-06-12 |
Family
ID=73653315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571944A Pending JP2022535417A (ja) | 2019-06-04 | 2020-06-02 | 骨髄細胞炎症性表現型を調節するための抗ｓｉｇｌｅｃ－９組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220396627A1 (https=) |
| EP (1) | EP3980462A4 (https=) |
| JP (1) | JP2022535417A (https=) |
| KR (1) | KR20220042056A (https=) |
| CN (1) | CN114401991A (https=) |
| AU (1) | AU2020288824A1 (https=) |
| BR (1) | BR112021024314A2 (https=) |
| CA (1) | CA3142433A1 (https=) |
| IL (1) | IL288511A (https=) |
| TW (1) | TW202110890A (https=) |
| WO (1) | WO2020247372A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11987612B2 (en) | 2019-11-04 | 2024-05-21 | Alector Llc | Siglec-9 ECD fusion molecules |
| AU2021329884A1 (en) * | 2020-08-17 | 2023-02-16 | SURGE Therapeutics, Inc. | Immune modulation of myeloid derived suppressive cell function for cancer treatment |
| WO2023192993A2 (en) * | 2022-03-31 | 2023-10-05 | The Wistar Institute Of Anatomy And Biology | Antibodies against human siglec-7 and use thereof for immunotherapy |
| US20250215078A1 (en) * | 2022-03-31 | 2025-07-03 | The Wistar Institute Of Anatomy And Biology | Antibodies Against Human Siglec-9 and Use Thereof for Immunotherapy |
| WO2024054527A1 (en) * | 2022-09-06 | 2024-03-14 | The Research Institute At Nationwide Children's Hospital | Genetically engineered bone marrow derived myeloid cells for treatment of central nervous system tumors |
| AU2023411024A1 (en) * | 2022-12-23 | 2025-08-07 | The Wistar Institute Of Anatomy And Biology | Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| CN117741143B (zh) * | 2024-02-20 | 2024-05-07 | 首都医科大学附属北京地坛医院 | Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用 |
| CN121281695B (zh) * | 2025-12-11 | 2026-03-31 | 山东师范大学 | 用于药物发现的分子生成方法、系统、介质及设备 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001352977A (ja) * | 2000-06-12 | 2001-12-25 | Kirin Brewery Co Ltd | 樹状細胞（ＤＣ）膜分子Ｓｉｇｌｅｃ−９に対する抗体、並びにそれを用いたＤＣ検出法及びＤＣ分離法 |
| CN101035807A (zh) * | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec－6相关疾病的诊断和治疗 |
| GB0521991D0 (en) * | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
| CA3003458A1 (en) * | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| WO2017123745A1 (en) * | 2016-01-12 | 2017-07-20 | Palleon Pharma Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| GB201611535D0 (en) * | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| AU2018298676A1 (en) * | 2017-07-10 | 2019-12-19 | Innate Pharma | Siglec-9-neutralizing antibodies |
-
2020
- 2020-06-02 CN CN202080056075.5A patent/CN114401991A/zh active Pending
- 2020-06-02 EP EP20818538.9A patent/EP3980462A4/en not_active Withdrawn
- 2020-06-02 KR KR1020217040139A patent/KR20220042056A/ko not_active Ceased
- 2020-06-02 AU AU2020288824A patent/AU2020288824A1/en not_active Abandoned
- 2020-06-02 JP JP2021571944A patent/JP2022535417A/ja active Pending
- 2020-06-02 TW TW109118528A patent/TW202110890A/zh unknown
- 2020-06-02 BR BR112021024314A patent/BR112021024314A2/pt not_active IP Right Cessation
- 2020-06-02 WO PCT/US2020/035703 patent/WO2020247372A1/en not_active Ceased
- 2020-06-02 CA CA3142433A patent/CA3142433A1/en active Pending
- 2020-06-02 US US17/615,861 patent/US20220396627A1/en not_active Abandoned
-
2021
- 2021-11-29 IL IL288511A patent/IL288511A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7238030B2 (ja) | Ｔ細胞療法のために患者をコンディショニングする方法 | |
| JP7305704B2 (ja) | Ｔ細胞療法のための診断方法 | |
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| JP2021529753A5 (https=) | ||
| US20220332828A1 (en) | Anti-pd-l1 antibody treatment of bladder cancer | |
| US12357646B2 (en) | Chimeric antigen receptor T cell therapy | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| TW202238129A (zh) | Ｔ細胞療法 | |
| JPWO2020247372A5 (https=) | ||
| JP2024507199A (ja) | 免疫療法を選択するための遺伝子マーカー | |
| JPWO2020247371A5 (https=) | ||
| JPWO2020263651A5 (https=) | ||
| JPWO2021243169A5 (https=) | ||
| JPWO2020263650A5 (https=) | ||
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| US20250290154A1 (en) | Predictive markers for immunotherapy | |
| CN120917153A (zh) | 肿瘤微环境对免疫疗法疗效的影响 | |
| JP2026071229A (ja) | 免疫療法由来の有害事象の予測 | |
| HK40078882A (en) | Chimeric antigen receptor t cell therapy |